Preclinical studies of a specific PPARγ modulator in the control of skin inflammation

Journal of Investigative Dermatology

Volumn 134, Issue 4, 2014, Pages 1001-1011

  Mastrofrancesco, Arianna ^a   Kovacs, Daniela ^a   Sarra, Massimiliano ^b   Bastonini, Emanuela ^a   Cardinali, Giorgia ^a   Aspite, Nicaela ^a   Camera, Emanuela ^a   Chavatte, Philippe ^c   Desreumaux, Pierre ^c   Monteleone, Giovanni ^b   Picardo, Mauro ^a  

^a SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; GED 0507 34L; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DERMATITIS; DISEASE CONTROL; EPIDERMIS HYPERPLASIA; EPITHELIUM HYPERPLASIA; HUMAN; HUMAN CELL; IMMUNOMODULATION; KERATINOCYTE; LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PSORIASIS; TOPICAL TREATMENT;

ACTIVE TRANSPORT, CELL NUCLEUS; ANILINE COMPOUNDS; ANIMALS; BIOPSY; CELL ADHESION; CELL PROLIFERATION; CELLS, CULTURED; CYCLOOXYGENASE 2; CYTOKINES; EPIDERMIS; HUMANS; INFLAMMATION; KERATINOCYTES; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; NF-KAPPA B; PHENYLPROPIONATES; PPAR GAMMA; PROPIONATES; PROTEIN BINDING; PSORIASIS; RNA INTERFERENCE; SKIN;

EID: 84897845679     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.448     Document Type: Article

References (53)

1. Bhagavathula N, Nerusu KC, Reddy M et al. (2005) BP-1107[{2-[4-(2, 4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-ethyl}-methyl-amide]: a novel synthetic thiazolidinedione that inhibits epidermal hyperplasia in psoriatic skin-severe-combined immunodeficient mouse transplants after topical application. J Pharmacol Exp Ther 315:996-1004
2. Bhalla K, Hwang BJ, Choi JH et al. (2011) N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor g ligand with partial and full agonist activity in vitro and in vivo. J Biol Chem 286:41626-35
3. Blackwell TS, Christman JW (1997) The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol 17:3-9
4. Bongartz T, Coras B, Vogt T et al. (2005) Treatment of active psoriatic arthritis with the PPARg ligand pioglitazone: an open-label pilot study. Rheumatology 44:126-9
5. Cariou B, Charbonnel B, Staels B. (2012) Thiazolidinediones and PPARg agonists: time for a reassessment. Trends Endocrinol Metab 23:205-15
6. Caruso R, Botti E, Sarra M et al. (2009) Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 15:1013-5
7. Chiba T, Takeuchi S, Esaki H et al. (2012) Topical application of PPARa (but not b/d or g) suppresses atopic dermatitis in NC/Nga mice. Allergy 67:936-42
8. Delerive P, Gervois P, Fruchart JC et al. (2000) Induction of IkBa expression as a mechanism contributing to the anti-inflammatory activities of peroxi-some proliferator-activated receptor-a activators. J Biol Chem 275: 36703-36707
9. Delerive P, Fruchart JC, Staels B (2001) Peroxisome proliferators- activated receptors in inflammation control. J Endocrinol 169:453-9
10. Demerjian M, Man MQ, Choi EH et al. (2006) Topical treatment with thiazolidinediones activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproli-ferative disease model. Exp Dermatol 15:154-60
11. Ellis CN, Barker JN, Haig AE et al. (2007) Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone. Am J Clin Dermatol 8:93-102
12. Flori E, Mastrofrancesco A, Kovacs D et al. (2011) 2, 4, 6-octatrienoic acid, is a novel promoter of melanogenesis and antioxidant defence in normal human melanocytes via PPARg activation. Pigment Cell Melanoma Res 24:618-30
13. Fridman JS, Scherle PA, Collins R et al. (2011) Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Invest Dermatol 131:1838-44
14. Gottlieb AB (2005) Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov 4:19-34
15. Hatano Y, Man MQ, Uchida Y et al. (2010) Murine atopic dermatitis responds to peroxisome proliferator-activated receptor a, b/d (but not g), and liver-X-receptor activators. J Allergy Clin Immunol 125:160-9
16. Hegazy RA, Abdel Hay RM, Shaker O et al. (2012) Psoriasis and metabolic syndrome: is peroxisome proliferator-activated receptor-g part of the missing link? Eur J Dermatol 22:622-8
17. Henson P (2003) Suppression of macrophage inflammatory responses by PPARs. Proc Natl Acad Sci USA 100:6295-6
18. Higgins LS, De Paoli AM (2010) Selective peroxisome proliferator- activated receptor g (PPARg) modulation as a strategy for safer therapeutic PPARg activation. Am J Clin Nutr 91(Suppl):267-72
19. Ishitsuka Y, Kawachi Y, Maruyama H et al. (2013) Pituitary tumor transforming gene 1 induces tumor necrosis factor-a production from keratinocytes: implication for involvement in the pathophysiology of psoriasis. J Invest Dermatol 133:2566-75
20. Kim BE, Howell MD, Guttman E et al. (2011) TNF-a downregulates filaggrin and loricrin through c-Jun N-terminal kinase: role for TNF-a antagonists to improve skin barrier. J Invest Dermatol 131:1272-9
21. Kovacs D, Flori E, Maresca V et al. (2012) The Eumelanin intermediate 5, 6-dihydroxyindole-2-carboxylic acid is a messenger in the cross-talk among epidermal cells. J Invest Dermatol 132:1196-205
22. Kuenzli S, Saurat JH (2003) Effect of topical PPARbeta/delta and PPARgamma agonists on plaque psoriasis. A pilot study. Dermatology 206:252-6
23. 2-mediated activation of NFkB-induced kinase. J Biol Chem 281:1495-505
24. Liberato MV, Nascimento AS, Ayers SD et al. (2012) Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) g activators and pan-PPAR partial agonists. PLoS One 7:e36297
25. Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of psoriasis. Nature 445:866-73
26. Malhotra A, Shafiq N, Rajagopalan S et al. (2012) Thiazolidinediones for plaque psoriasis: a systematic review and meta-analysis. Evid Based Med 17:171-6
27. Mao-Qiang M, Fowler AJ, Schmuth M et al. (2004) Peroxisome-proliferator- activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation. J Invest Dermatol 123:305-12
28. Man MQ, Choi EH, Schmuth M et al. (2006) Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. J Invest Dermatol 126:386-92
29. Marx N, Kehrle B, Kohlhammer K et al. (2002) PPAR activators as antiin-flammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 90:703-10
30. Mastrofrancesco A, Ottaviani M, Aspite N et al. (2010) Azelaic acid modulates the inflammatory response in normal human keratinocytes through PPARg activation. Exp Dermatol 19:813-20
31. Michalik L, Wahli W (2007) Peroxisome proliferators-activated receptors (PPARs) in skin health, repair and disease. Biochim Biophys Acta 1771:991-8
32. Navarro JM, Casatorres J, Jorcano JL (1995) Elements controlling the expression and induction of the skin hyperproliferation-associated keratin K6. J Biol Chem 270:21362-7
33. Nestle FO, Kaplan DH, Barker J (2009a) Psoriasis. N Engl J Med 361:496-509
34. Nesto RW, Bell D, Bonow RO et al. (2003) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108:2941-8
35. Pascual G, Glass CK (2006) Nuclear receptor versus inflammation: mechanisms of transrepression. Trends Endocrinol Metab 17:321-7
36. Pasparakis M (2009) Regulation of tissue homeostasis by NF-kappaB signalling: implications for inflammatory diseases. Nat Rev Immunol 9:778-88
37. Pirat C, Farce A, Renault N et al. (2012) Targeting PPARs: development of modulators. J Med Chem 55:4027-61
38. Qiang MM, Fowler AJ, Schmuth M et al. (2004) Peroxisome-proliferator- activated receptor (PPAR)-g activation stimulates keratinocytes differenta-tion. J Invest Dermatol 123:305-12
39. Rocchi S, Picard F, Vamecq J et al. (2001) A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 8:737-47
40. Rousseaux C, Lefebvre B, Dubuquoy L et al. (2005) Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 201:1205-15
41. + cells and driver IFN-g dependent epidermal hyperplasia. J Immunol 186:5435-42
42. Sears DD, Hsiao A, Ofrecio JM et al. (2007) Selective modulation of promoter recruitment and transcriptional activity of PPARg. Biochem Biophys Res Comm 364:515-21
43. Semple RK, Chatterjee VK, O'Rahilly S (2006) PPAR gamma and human metabolic disease. J Clin Invest 116:581-9
44. Sertznig P, Seifert M, Tilgen W et al. (2008) Peroxisome proliferator-activated receptors (PPARs) and the human skin. Am J Clin Dermatol 9:15-31
45. Sertzing P, Reichrath J (2011) Peroxisome proliferator-activated receptors (PPARs) in dermatology. Challenge and promise. Dermatoendocrinol 3:130-5
46. Shafiq N, Malhotra S, Pandhi P et al. (2005) Pilot trial: pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int J Dermatol 44: 328-333
47. Shin KM, Shen L, Park SJ et al. (2009) Bis-(3-hydroxyphenyl) diselenide inhibits LPS-stimulated iNOS and COX-2 expression in RAW 264, 7 macrophage cells through the NF-kappa B inactivation. J Pharm Pharmacol 61:479-86
48. Sugiyama H, Nonaka T, Kishimoto T et al. (2000) Peroxisome proliferator-activated receptors are expressed in human cultured mast cells: a possible role of these receptors in negative regulation of mast cell activation. Eur J Immunol 30:3363-70
49. Tomic-Canic M, Komine M, Freedberg IM et al. (1998) Epidermal signal transduction and transcription factor activation in activated keratinocytes. J Dermatol Sci 17:167-81
50. Wahli W, Michalik L (2012) PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab 23:351-63
51. Weiss RA, Eichner R, Sun TT (1984) Monoclonal antibody analysis of keratin expression in epidermal diseases: a 48-and 56-kdalton keratin as molecular markers for hyperproliferative keratinocytes. J Cell Biol 98:1397-406
52. Westergaard M, Henningsen J, Johansen C et al. (2003) Expression and localization of peroxisome proliferators-activated receptors and nuclear factor kB in normal and lesional psoriatic skin. J Invest Dermatol 121:1104-17
53. Yang T, Soodvilai S (2008) Renal and vascular mechanisms of thiazolidine-dione-induced fluid retention. PPAR Res 2008:943614